168835-82-3

Basic information

• Product Name: (E)-2-cyano-3-(4-hydroxy-3,5-diisopropylphenyl)-N-(3-phenylpropyl)acrylamide
• Synonyms: (E)-2-cyano-3-(4-hydroxy-3,5-diisopropylphenyl)-N-(3-phenylpropyl)acrylamide;(E)-2-cyano-3-(4-hydroxy-3,5-diisopropylphenyl)-N-(3-phenylpropy
• CAS NO: 168835-82-3
• Molecular Formula: C25H30N2O2
• Molecular Weight: 390.5179
• Mol File: 168835-82-3.mol

Chemical Properties

• Melting Point: 126 °C
• Boiling Point: 590.6±50.0 °C(Predicted)
• Appearance: /
• Density: 1.100±0.06 g/cm3(Predicted)
• Storage Temp.: -20°C
• Solubility: Soluble in DMSO.
• PKA: 10.30±0.36(Predicted)
• Stability: Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months.
• CAS DataBase Reference: (E)-2-cyano-3-(4-hydroxy-3,5-diisopropylphenyl)-N-(3-phenylpropyl)acrylamide(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-2-cyano-3-(4-hydroxy-3,5-diisopropylphenyl)-N-(3-phenylpropyl)acrylamide(168835-82-3)
• EPA Substance Registry System: (E)-2-cyano-3-(4-hydroxy-3,5-diisopropylphenyl)-N-(3-phenylpropyl)acrylamide(168835-82-3)

Safety Data

• Hazardous Substances Data: 168835-82-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(E)-2-cyano-3-(4-hydroxy-3,5-diisopropylphenyl)-N-(3-phenylpropyl)acrylamide is used as a pharmaceutical agent for its potential therapeutic effects. (E)-2-cyano-3-(4-hydroxy-3,5-diisopropylphenyl)-N-(3-phenylpropyl)acrylamide's unique structure allows it to interact with specific biological targets, such as enzymes or receptors, modulating their activity and contributing to the treatment of various diseases.
Used in Chemical Research:
In the field of chemical research, (E)-2-cyano-3-(4-hydroxy-3,5-diisopropylphenyl)-N-(3-phenylpropyl)acrylamide serves as a valuable compound for studying the structure-activity relationships of similar molecules. Its synthesis and modification can provide insights into the design of new drugs and the understanding of molecular interactions.
Used in Biochemical Applications:
(E)-2-cyano-3-(4-hydroxy-3,5-diisopropylphenyl)-N-(3-phenylpropyl)acrylamide can be employed in biochemical applications as an inhibitor or activator of specific enzymes or proteins. Its ability to modulate the activity of these biomolecules can be utilized in the development of diagnostic tools or therapeutic agents.

Biochem/physiol Actions

SU1498 is a potent and selective inhibitor of the VEGFR2 receptor kinase, Flk-1 with an IC50 value of 700 nM. SU1498 is a very weak inhibitor of PDGFR-kinase, EGFR-kinase and HER-2 kinase with IC50 values > 50 μM. SU1498 has been used to study the role of VEGFR2 (Flk-1) in a variety of biological activities including angiogenesis, tumor growth inhibition, and stem cell proliferation.

References

1) Cho et al. (2005), Retinoic acid and erythropoietin maintain alveolar development in mice treated with an angiogenesis inhibitor; Am. J. Respir. Cell Mol. Biol., 33 622 2) Wang et al. (2002), Interplay between integrins and FLK-1 in shear stress-induced signaling; Am. J. Physiol. Cell Physiol., 283 C1540 3) Strawn et al. (1996), FLK-1 as a target for tumor growth inhibition; Cancer Res., 56 3540

Upstream product

• 10537-86-7 3,5-diisopropyl-4-hydroxybenzaldehyde 
• 133550-33-1 N-(3-phenyl-n-propyl)-cyanoacetamide 
• 2078-54-8 2,6-diisopropylphenol 
• 2038-57-5 3-Phenylpropan-1-amine 

Relevant articles and documents

Preparation method VEGFR2 selective inhibitor SU1498

The preparation method comprises the following steps VEGFR2: firstly converting diisopropyl phenol to SU1498 hydroxyl - 3333, 5-diisopropylphenyl,propyl SU1498 acrylamide 2 - to obtain the target product) - N - (3 - and obtaining)-cyan- 3 3 3 3 3-diisopropyl phenyl- acrylamide: The preparation method disclosed by the invention is low in cost, easy to obtain :2,6 - and high 4 - purity . in total yield after simple 2 -process method. (E)- 2 - The preparation method disclosed by the invention is simple, and, easy to obtain, the, final product)-cyanacetic acid, and the preparation, method of.selectivity inhibitor, is shown in the present invention.